SCHEMBL43493

SCHEMBL43493

COCC(=O)c1cccc(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.55
CES1 P23141 1/20 0.55
PARP1 P09874 1/20 0.52
LMNA P02545 5/20 0.50
KDM4E B2RXH2 4/20 0.50
NPC1 O15118 4/20 0.50
KMT2A Q03164 4/20 0.50
MAPT P10636 3/20 0.50
HPGD P15428 3/20 0.50
HTT P42858 3/20 0.50
MEN1 O00255 3/20 0.50
RAB9A P51151 3/20 0.50
TSHR P16473 2/20 0.50
ALOX12 P18054 1/20 0.50
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
KCNH2 Q12809 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HDAC1 Q13547 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3165423 0.83 CES2 (0.52) CES2CES1PARP1LMNAKDM4E
SCHEMBL6099390 0.82 ERCC5 (0.50) LMNAKDM4EKMT2AHPGDHTT
SCHEMBL2056918 0.81 MEN1 (0.56) CES2CES1PARP1LMNAKDM4E
SCHEMBL7649275 0.80 CES2 (0.49) CES2CES1PARP1LMNAKDM4E
SCHEMBL7647919 0.80 CES2 (0.49) CES2CES1PARP1LMNAKDM4E
SCHEMBL1210113 0.80 CTNNB1 (0.58) PARP1LMNAKDM4ENPC1KMT2A
SCHEMBL7285469 0.80 ESR1 (0.53) PARP1KDM4ENPC1MAPTRAB9A
SCHEMBL11267206 0.80 KMT2A (0.47) KMT2AHPGDRAB9ASMN1; SMN2HSD17B10
SCHEMBL31309786 0.80 CTNNB1 (0.58) PARP1LMNAKDM4ENPC1KMT2A
SCHEMBL16994152 0.80 MEN1 (0.46) LMNAKDM4ENPC1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028600-A1 TRANSAMINASE POLYPEPTIDES CODEXIS INC (US) 2026-01-29 US disclosed
US-12448611-B2 Transaminase polypeptides CODEXIS, INC. (US) 2025-10-21 US disclosed
EP-4608802-A1 USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS XV BASF SE (DE) 2025-09-03 EP disclosed
US-12378537-B2 Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs CODEXIS, INC. (US) 2025-08-05 US disclosed
CN-120091993-A Use of strobilurin type compounds for combating phytopathogenic fungi comprising the amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitor XV 巴斯夫欧洲公司 2025-06-03 CN disclosed
US-12305201-B2 Engineered biocatalysts and methods for synthesizing chiral amines CODEXIS, INC. (US) 2025-05-20 US disclosed
US-20250101389-A1 BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS CODEXIS INC (US) 2025-03-27 US disclosed
CN-119698468-A Biocatalysts and methods thereof 特沙诺有限公司 2025-03-25 CN disclosed
US-12163162-B2 Biocatalysts and methods for the synthesis of substituted lactams CODEXIS, INC. (US) 2024-12-10 US disclosed
US-20240150732-A1 TRANSAMINASE POLYPEPTIDES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2024-05-09 US disclosed
EP-1075534-B8 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 2005-07-06 EP disclosed
EP-1075534-B1 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 2005-05-11 EP disclosed
EP-1075534-A4 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 2003-07-09 EP disclosed
EP-1075534-A1 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES Celgro (US) 2001-02-14 EP disclosed
US-6133018-A Enzymatic synthesis of chiral amines using -2-amino propane as amine donor CELGRO (US) 2000-10-17 US disclosed
WO-1999046398-A1 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 1999-09-16 WO disclosed
EP-0203791-B1 SPIRO-IMIDAZOLIDINES AS ALDOSE REDUCTASE INHIBITORS PFIZER INC. (US) 1989-09-13 EP disclosed
EP-0203791-A1 Spiro-imidazolidines as aldose reductase inhibitors PFIZER INC. (US) 1986-12-03 EP disclosed
US-4575507-A COMPLICATIONS OF DIABETES PFIZER INC. (US) 1986-03-11 US disclosed
US-4251546-A Process for killing internal helminths using certain 1,1-bis-(2-substituted-3-nitrophenyl)alkane or alkylene derivatives ICI AUSTRALIA LIMITED (AU) 1981-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101389-A1 BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS BCAT1, GOT1, OAT CES2 176/4885CES1 192/4885PARP1 1304/4885
US-20260028600-A1 TRANSAMINASE POLYPEPTIDES GOT1, OAT, PEPD CES2 419/4885CES1 100/4885PARP1 1345/4885
US-12163162-B2 Biocatalysts and methods for the synthesis of substituted lactams BCAT1, GOT1, OAT CES2 176/4885CES1 192/4885PARP1 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.